Valaminols, probably the most simplified peptide-analogs acting as pepsin inhibitors

Peptides

Volumn 21, Issue 2, 2000, Pages 289-293

  Kratzel, Martin ^a   Bernkop Schnürch, Andreas ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Enzyme inhibitors; Pepsin inhibition; Pepstatin A; Pepstatin analogs

Indexed keywords

AMINOALCOHOL; PEPSIN A; PEPSIN INHIBITOR; PEPSTATIN; PEPSTATIN DERIVATIVE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VALINE;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; COST; DRUG SYNTHESIS; ENZYME INHIBITION; MASS SPECTROMETRY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

DRUG DESIGN; HORSERADISH PEROXIDASE; MOLECULAR STRUCTURE; OLIGOPEPTIDES; PEPSIN A; PEPSTATINS; PEPTIDES; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034109384     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(99)00196-5     Document Type: Article

References (16)

1. Bernkop-Schnürch A., Dundalek K. Novel bioadhesive drug delivery system protecting (poly)peptides from gastric enzymatic degradation. Int J Pharm. 138:1996;75-83.
2. Bernkop-Schnürch A. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J Control Release. 52:1998;1-16.
3. Bernkop-Schnürch A. Polymer-inhibitor conjugates a promising strategy to overcome the enzymatic barrier to perorally administered (poly)peptide drugs? S.T.P. Pharma Sci. 9:1999;78-87.
4. Bernkop-Schnürch A., Kirchmayer R., Kratzel M. Synthesis, development and in vitro evaluation of drug delivery systems with protective effect towards pepsinic degradation. J Drug Target. 7:1999;55-63.
5. Cho Y.-K., Rebholz K.L., Northrop D.B. Solvent isotope effects on the onset of inhibition of porcine pepsin by pepstatin. Biochemistry. 33:1994;9637-9642.
6. Edwards C.R., Padfield P.L. Angiotensin-converting enzyme inhibitors Past, present, and bright future . Lancet. 1:1985;30-34.
7. Fujii S., Yokoyama T., Ikegaya K., Sato F., Yokoo N. Promoting effect of the new chymotrypsin inhibitor FK-448 on the intestinal absorption of insulin in rats and dogs. J. Pharm Pharmacol. 37:1985;545-549.
8. Kratzel M., Hiessböck R., Bernkop-Schnürch A. Auxiliary agents for the peroral administration of peptide and protein drugs Synthesis and evaluation of novel pepstatin analogues . J Med Chem. 41:1998;2339-2344.
9. Kratzel M., Schlichtner B., Kirchmayer R., Bernkop-Schnürch A. Simplified pepstatins Synthesis and evaluation of N-terminally modified analogues . J Med Chem. 42:1999;2041-2045.
10. Langguth P., Merkle H.P., Amidon G.L. Oral absorption of peptides The effect of absorption site and enzyme inhibition on the systemic availability of metkephamid . Pharmacol Res. 11:1994;528-535.
11. Leto G., Pizzolanti G., Tumminello F.M., Gebbia N. Effects of E-64 (cysteine-proteinase inhibitor) and pepstatin (aspartyl-proteinase inhibitor) on metastasis formation in mice with mammary and ovarian tumors. In Vivo. 8:1994;231-236.
12. Lin C., Frishman W.H. Renin inhibition A novel therapy for cardiovascular disease . Am Heart J. 131:1996;1024-1034.
13. McConnell R.M., Frizzell D., Evans A.C.A., Jones W., Cagle C. New pepstatin analogues Synthesis and pepsin inhibition . J Med Chem. 34:1991;2298-2300.
14. Tyagi S.C. Inhibitors of human immunodeficiency virus-1 protease. Biochem Cell Biol. 70:1992;309-315.
15. Yamamoto A., Taniguchi T., Rikyuu K., Tsuji T., Fujita T., Murakami M., Muranishi S. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharmacol Res. 11:1994;1496-1500.
16. Yang J., Quail J.W. Structure of the Rhizomucor michei aspartic proteinase complexed with the inhibitor pepstatin A at 2.7 Å resolution. Acta Crystallogr D Biol Crystallogr. 55:1999;625-630.